The Global Electroceutical
Devices Market, by Product Type (Cardiac Pacemakers, Implantable Cardioverter Defibrillators, Cardiac Resynchronization Therapy Devices, Retinal Implants, Cochlear Implants, Spinal cord Stimulators, Deep brain Stimulators, Sacral Neuromodulators and Others), by Modality (Implantable Electroceutical
Devices and Non-Invasive Electroceutical
Devices), by Application (Chronic Pain, Cardiovascular Diseases, Ophthalmic Diseases, Neurological Diseases, Hearing Disorders and Gastrointestinal Diseases), By End User (Hospitals, Ambulatory Surgical Centers and Others), was valued US$ 17.1 billion in 2018, and is projected to exhibit a CAGR of 6.8% over the forecast period (2018 - 2026) as highlighted in a new report published by Coherent Market Insights.
The internal electroceutical
segment held the largest market revenue in 2015 and is expected to grow by 2022 growing at a high CAGR from 2015 to 2022 due to technological advancement in wireless micro current stimulation, wearable pain management technology, miniaturization etc.
are medical devices that use electrical impulses to modulate the body's neural circuits as an alternative to drug-based interventions.
If all goes according to plan, GSK hopes to have the first electroceutical
medicine ready for approval within the next several years.
may be the most promising and fastest-growing alternative to drugs.
The trial sponsored by electroCore, one of the world leaders in the rapidly expanding field of electroceuticals
, is part of the most comprehensive clinical trial programs in headache presently running.
The company's Electroceuticals
have been used in non-invasive treatments for a wide array of conditions, including chronic wounds, pain and edema following plastic and reconstructive surgery and chronic inflammatory disorders.
Another trial on migraine abortion, which was identically designed to the trials testing abortive migraine medications, showed excellent efficacy outcomes for the Cefaly treatment, an electroceuticals
, that outperformed published data on triptans as well as new medical drugs currently under investigation: Lasmiditan, Ubrogepant, Rimegepant.
- Increasing investments for the development of electroceuticals
(OTCQB: ENDV) has executed a binding letter of intent to acquire Santa Fe, New Mexico-based electroceuticals
developer Rio Grande Neurosciences, Inc., the company said.
Overall market growth can be contributed to rising geriatric population, regulatory approval for new and advanced electroceuticals
, growing investments and funds for the development of novel therapies and electroceuticals
, rising prevalence of neurological disorders, and growing prevalence of hearing loss.